954138-07-9

Upstream product

• 954138-53-5 7-chloro-3-[4-(2-hydroxyethyl)piperazin-1-yl]-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one 
• 163105-89-3 2-methoxy-pyridine-5-boronic acid 
• 915307-80-1 6-chloro-N₄-(2-propoxy-ethyl)-pyridine-3,4-diamine 
• 1186508-07-5 7-chloro-1-(2-propoxy-ethyl)-1,4-dihydro-pyrido[3,4-b]pyrazine-2,3-dione 
• 915307-81-2 3,7-dichloro-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 
• 915307-78-7 tert-butyl (6-chloro-4-fluoropyridin-3-yl)carbamate 
• 915307-79-8 [6-chloro-4-(2-propoxy-ethylamino)-pyridin-3-yl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)

The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ

Pyridine [3,4-b] Pyrazinones

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.